HER-2-Targeted T Cells May Have a Role in Ovarian Cancer Treatment

April 21, 2010

(PhysOrg.com) -- Ovarian cancer is the most lethal reproductive cancer for women, with just one-fifth of women diagnosed with advanced disease surviving five years. It is frequently reported that less than one-third of ovarian cancers overexpress the HER-2 protein, which is the molecular target of trastuzumab (Herceptin).

However, with more sensitive detection methods, Daniel J. Powell, Jr., PhD, a research assistant professor of Pathology and Laboratory Medicine and Obstetrics and Gynecology at the University of Pennsylvania School of Medicine, and colleagues found that virtually all ovarian cancers express HER-2. The novel findings suggest that therapy targeting HER-2 may have a role in ovarian in the future, and may improve the outcome for with ovarian cancer the way it has for women with HER-2 expressing .

The team used three different assays to test for HER-2 expression in ovarian cancer cell lines and patient tumor samples. “What we found is that ovarian cancers ubiquitously express HER-2, and generally at higher levels than normal ovary tissue,” says Powell, whose group presented their findings Tuesday, April 20th at the American Association of Cancer Research meeting.

Although the results of previous clinical trials testing trastuzumab in women with advanced ovarian cancer have been lackluster, Powell thinks responses could be improved by using genetically engineered to deliver a toxic hit to tumor expressing HER-2. The modified T cells express an engineered protein - called a chimeric immune receptor -- that combines a portion of an anti-HER-2 antibody with a portion of a killer T-cell receptor to stimulate cell-killing activity. “The chimeric immune receptor is not simply binding the HER-2 protein; it also uses the power of killer T cells coming in behind to further mediate the anti-tumor response,” Powell explains. “Also, the chimeric immune receptor that we are using is able to distinguish recognition of ovarian cancer from normal targets, despite the fact that the normal cells do express HER-2.”

The new results support testing of anti-HER-2 T-cell therapy in , but Powell cautions that more research is needed to understand how to deliver the cells safely.

Explore further: 'Clumping' protein linked to return of ovarian cancer

Related Stories

'Clumping' protein linked to return of ovarian cancer

December 15, 2006

Johns Hopkins scientists have discovered that women treated for ovarian cancer are at increased risk of a rapid and potentially fatal recurrence if their tumor cells have high levels of a binding protein that triggers abnormal ...

Vascular marker of ovarian cancer identified

September 23, 2008

Researchers have identified TEM1 as a specific genetic marker for the vascular cells associated with tumor growth, a finding that could aid in diagnosis and treatment of ovarian cancer.

Study links obesity to elevated risk of ovarian cancer

January 5, 2009

A new epidemiological study has found that among women who have never used menopausal hormone therapy, obese women are at an increased risk of developing ovarian cancer compared with women of normal weight. Published in the ...

Targeted Immune Cells Shrink Tumors in Mice

February 10, 2009

(PhysOrg.com) -- Researchers have generated altered immune cells that are able to shrink, and in some cases eradicate, large tumors in mice. The immune cells target mesothelin, a protein that is highly expressed, or translated ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.